The encyclopedia · Product & Design · Product decision · 2010–2012
NeuroSearch's lead drug failed in Phase III — a Danish biotech evaporated in two years
Danish biotech NeuroSearch spent 20 years on Pridopidine. The Phase III trial failed in 2010. By 2012, the company had no funding and sold its only asset.
NeuroSearch · 2010-06
What happened
NeuroSearch was founded in 1989 in the Medicon Valley region of Denmark. It was one of the country's first biotech companies, listed on NASDAQ OMX Copenhagen in 1996. Over two decades, the company built a pipeline around central nervous system drugs, with Pridopidine for Huntington's disease as its lead candidate. The company had raised significant private and public investment and acquired Carlsson Research in 2006.
In 2010, Pridopidine failed its Phase III MermaiHD study — the drug did not meet its primary endpoint of improving motor function in Huntington's disease patients. The failure was absolute: NeuroSearch had no other late-stage pipeline assets to fall back on. The company's entire value was tied to Pridopidine's success.
By 2012, NeuroSearch could no longer attract funding for its R&D activities. It sold the rights to Pridopidine to Teva Pharmaceutical Industries for a fraction of what it had invested. The development of all remaining pipeline projects was stopped. The company tried to sell its remaining assets, and in 2014 transferred the rights to its obesity drug tesofensine to Saniona. In 2018, a Danish transport company acquired all NeuroSearch shares. The biotech that had been one of Denmark's pioneering life science companies was gone.
Why it happened
- NeuroSearch bet everything on a single drug — Pridopidine was its only late-stage asset, and when the Phase III trial failed, the company had nothing to fall back on.
- The two-decade development cycle meant the company had burned through years of investor capital before reaching the failure point, leaving no financial buffer for a second attempt.
- After the trial failure, the company could not raise new funding — investors saw a biotech with a failed lead drug, no pipeline depth, and no clear path to revenue.
The lesson
One drug, one trial, one shot. Biotechs that live or die on a single Phase III result are not companies — they are lottery tickets. NeuroSearch lost.
Aftermath
Pridopidine was acquired by Teva and later by Prilenia Therapeutics, which continued development. Tesofensine was transferred to Saniona in 2014. In 2018, transport company NTG acquired all NeuroSearch shares. The company name and identity were dissolved.
Sources
spotted an error? The club wants to know.
More like this
Daiichi Sankyo's ADC bet: capacity locked in before the patients existed
Optiray 350: glass and steel in the contrast vial
Adequan: glass fiber in the joint injection for dogs and horses
Somewhere, someone solved the problem this company failed at. 2nd Opinion →
Comments · 0
Sign in to join the comments.